技術(shù)文章
- 一文帶你了解qPCR原理與流程,建議收藏再看!
- 一種重組人粒細(xì)胞刺激因子的生產(chǎn)方法
- 細(xì)胞培養(yǎng)輔助試劑的檢查和觀察方法
- T淋巴細(xì)胞培養(yǎng)基的開(kāi)發(fā)與應(yīng)用,助力免疫疾病治療新突破
- 細(xì)胞凍存液的功能及配比介紹
- 高效準(zhǔn)確:淋巴細(xì)胞分離液在生物醫(yī)學(xué)研究中的應(yīng)用
- 優(yōu)化實(shí)驗(yàn)流程:淋巴細(xì)胞分離液助力免疫細(xì)胞分析新突破
- 流式細(xì)胞術(shù)之檢測(cè)工作原理
- Corning SyntheGel基質(zhì)膠系列,升級(jí)您的iPSC細(xì)胞治療研究
- 細(xì)胞培養(yǎng)輔助試劑的基本實(shí)驗(yàn)操作
2014年1月3日訊
zui近來(lái)自威爾士的研究人員研究發(fā)現(xiàn)干細(xì)胞技術(shù)有望能夠修復(fù)受損的心臟組織。研究人員認(rèn)為這一成果令人激動(dòng),并預(yù)期這一技術(shù)可能會(huì)在未來(lái)五年內(nèi)進(jìn)入臨床 階段用于治療心臟疾病。Cell Therapy Limited公司的CEO Ajan Reginald介紹說(shuō)研究人員確定了一種能夠?qū)R环只癁樾呐K組織細(xì)胞的干細(xì)胞,利用這種干細(xì)胞人們將可能能修復(fù)心臟病患者的心臟受損部位,zui終治愈心臟 病。Ajan Reginald容是還透露目前公司正在進(jìn)行關(guān)于該技術(shù)安全性的早期臨床研究,現(xiàn)在得到的數(shù)據(jù)十分光明。Cell Therapy Limited公司認(rèn)為這項(xiàng)技術(shù)如果能夠zui終成功將對(duì)整個(gè)威爾士地區(qū)都帶來(lái)巨大的益處。(生物谷Bioon.com)
詳細(xì)英文報(bào)道:
Research by a team of scientists in Wales has shown early signs of being able to regenerate damaged heart tissue.
By experimenting at Cardiff and Swansea university laboratories, Cell Therapy hopes to develop new treatments for heart failure over the next five years.
Signs from early stem cell trials "look very positive", it said.
Ex-First Minister Rhodri Morgan, a company director, said it could bring a cure for incurable heart disease.
The research team was co-founded by Nobel prize-winning scientist Sir Martin Evans, who first isolated and grew embryonic stem cells in the 1980s.
Cell Therapy Limited's executive director Ajan Reginald told BBC Wales: "We've identified what we think is a very potent type of stem cell which is heart specific.
'Very scary'
"And what our therapy does is to produce more of those so that you have a large number of those cells to help you to regenerate the part of the heart that is damaged.
"We've finished our first clinical trial which was focused on safety. The interim analysis looks very positive and very fortunay we've also seen some benefit - the study does show some signs of early regeneration."
One of the company's directors, former first minister Rhodri Morgan has a very personal history with heart disease.
In July 2007, weeks after a gruelling assembly election campaign, Mr Morgan suffered a heart attack.
Talks about a coalition cabinet were put on hold as the then first minister had "stents" inserted into two blocked arteries.
"It was very scary," Mr Morgan told BBC Wales, "in your heart of hearts you know - this is the big one."
Welsh label
"But I was very lucky because there was no permanent damage to my heart."
Almost exactly 50 years earlier Mr Morgan had seen his father go through the same experience.
"I'll always remember helping the ambulance man carry my father down the stairs," he said.
"Heart disease has always been up there consciously for my brother and myself."
Mr Morgan's involvement with Cell Therapy is his first role in the private sector.
He said he wants to strengthen the company's Welsh roots.
"If we can bring it off this would represent a cure for people with incurable heart disease.
"That's a tremendous advantage but the fact that it would have a Welsh label on it as well would be tremendous for Wales."